ClinicalTrials.gg
Drug

APIM-containing Peptide ATX-101 clinical trials

Also written ATX-101.

studies test it
16
open now
0
in phase 3
2
first study started
2008

How each study uses APIM-containing Peptide ATX-101 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Development codes

ATX-101
11

Studies by the year they started

15 studies that test it; most in 2008 (2)

Studies that test APIM-containing Peptide ATX-101, by start year
YearStudies
20082
20091
20101
20111
20122
20131
20141
20171
20211
20222
20252

By phase

A phase 1/2 study counts in both.

Phase 1
9
Phase 2
5
Phase 3
2
No phase
1

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 14 · Other 2

Kythera Biopharmaceuticals (10) · Allay Therapeutics, Inc. (2) · Aurobac Therapeutics SAS (1) · Northwestern University (1) · THERAPIM PTY LTD (1) · Benjamin Izar (1)

Often tested with

Tested in the same studies.

Moxifloxacin (1) · Carboplatin (1) · Liposomal doxorubicin (1) · Doxorubicin (1)

Studies

Open first, then newest update. How each study uses APIM-containing Peptide ATX-101 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 16

What changed recently

From the registry's own updates since Oct 18, 2026.